|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/18 AIM ImmunoTech Inc. 10-K 12/31/17 88:14M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.27M
2: EX-4.8 Instrument Defining the Rights of Security Holders HTML 67K
3: EX-10.45 Material Contract HTML 29K
4: EX-10.46 Material Contract HTML 29K
5: EX-10.47 Material Contract HTML 30K
6: EX-10.48 Material Contract HTML 30K
7: EX-10.57 Material Contract HTML 214K
14: EX-10.58 Material Contract HTML 194K
15: EX-10.59 Material Contract HTML 40K
16: EX-21 Subsidiaries List HTML 24K
17: EX-23.1 Consent of Experts or Counsel HTML 26K
18: EX-31.1 Certification -- §302 - SOA'02 HTML 32K
19: EX-31.2 Certification -- §302 - SOA'02 HTML 32K
20: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
21: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
22: R1 Document and Entity Information HTML 52K
23: R2 Consolidated Balance Sheets HTML 92K
24: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K
25: R4 Consolidated Statements of Comprehensive Loss HTML 78K
26: R5 Consolidated Statements of Changes in HTML 72K
Stockholders' Equity
27: R6 Consolidated Statements of Cash Flows HTML 112K
28: R7 Business HTML 35K
29: R8 Summary of Significant Accounting Policies HTML 56K
30: R9 Inventories HTML 32K
31: R10 Marketable Securities HTML 50K
32: R11 Patents, Trademark Rights and Other Intangibles HTML 29K
(FASB ASC 350-30 General Intangibles Other than
Goodwill)
33: R12 Accrued Expenses HTML 31K
34: R13 Stockholders' Equity HTML 186K
35: R14 Segment and Related Information HTML 28K
36: R15 Research, Consulting and Supply Agreements HTML 41K
37: R16 401(k) Plan HTML 30K
38: R17 Royalties, License and Employment Agreements HTML 33K
39: R18 Leases HTML 28K
40: R19 Income Taxes (FASB ASC 740 Income Taxes) HTML 40K
41: R20 Notes Payable HTML 29K
42: R21 Certain Relationships and Related Transactions HTML 30K
43: R22 Concentrations of Credit Risk HTML 27K
44: R23 Fair Value HTML 76K
45: R24 Subsequent Events HTML 35K
46: R25 Summary of Significant Accounting Policies HTML 97K
(Policies)
47: R26 Summary of Significant Accounting Policies HTML 31K
(Tables)
48: R27 Inventories (Tables) HTML 31K
49: R28 Marketable Securities (Tables) HTML 52K
50: R29 Accrued Expenses (Tables) HTML 30K
51: R30 Stockholders' Equity (Tables) HTML 162K
52: R31 Income Taxes (FASB ASC 740 Income Taxes) (Tables) HTML 33K
53: R32 Fair Value (Tables) HTML 65K
54: R33 Business (Details Narrative) HTML 48K
55: R34 Summary of Significant Accounting Policies HTML 64K
(Details Narrative)
56: R35 Summary of Significant Accounting Policies - HTML 36K
Schedule of Property and Equipment (Details)
57: R36 Inventories (Details Narrative) HTML 27K
58: R37 Inventories - Schedule of Inventories (Details) HTML 32K
59: R38 Marketable Securities (Details Narrative) HTML 27K
60: R39 Marketable Securities - Schedule of Available for HTML 42K
Sale (Details)
61: R40 Marketable Securities - Schedule of Investments HTML 46K
with Continuous Unrealized Losses (Details)
62: R41 Patents, Trademark Rights and Other Intangibles HTML 50K
(FASB ASC 350-30 General Intangibles Other than
Goodwill) (Details Narrative)
63: R42 Accrued Expenses - Schedule of Accrued Expenses HTML 37K
(Details)
64: R43 Stockholders' Equity (Details Narrative) HTML 291K
65: R44 Stockholders' Equity - Schedule of Options and HTML 42K
Equity Estimated Based on Weighted Average
Assumptions (Details)
66: R45 Stockholders' Equity - Schedule of Stock Option HTML 99K
Activity Plans (Details)
67: R46 Stockholders' Equity - Schedule of Stock Option HTML 95K
Activity (Details)
68: R47 Stockholders' Equity - Schedule of Unvested Stock HTML 66K
Option Activity (Details)
69: R48 Stockholders' Equity - Schedule of Warrants HTML 73K
Outstanding and Exercisable (Details)
70: R49 Segment and Related Information (Details HTML 26K
Narrative)
71: R50 Research, Consulting and Supply Agreements HTML 66K
(Details Narrative)
72: R51 401(k) Plan (Details Narrative) HTML 35K
73: R52 Royalties, License and Employment Agreements HTML 52K
(Details Narrative)
74: R53 Leases (Details Narrative) HTML 26K
75: R54 Income Taxes (FASB ASC 740 Income Taxes) (Details HTML 52K
Narrative)
76: R55 Income Taxes (FASB ASC 740 Income Taxes) - HTML 47K
Schedule of Deferred Tax Assets and Liabilities
(Details)
77: R56 Note Payable (Details Narrative) HTML 41K
78: R57 Certain Relationships and Related Transactions HTML 43K
(Details Narrative)
79: R58 Concentrations of Credit Risk (Details Narrative) HTML 28K
80: R59 Fair Value (Details Narrative) HTML 33K
81: R60 Fair Value - Schedule of Assumptions to Estimate HTML 64K
Fair Value of Warrants (Details)
82: R61 Fair Value - Schedule of Range of Probabilities HTML 29K
(Details)
83: R62 Fair Value - Schedule of Assets and Liabilities HTML 34K
Measured at Fair Value on a Recurring Basis
(Details)
84: R63 Fair Value - Schedule of Changes in Level 3 HTML 34K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
85: R64 Subsequent Events (Details Narrative) HTML 71K
87: XML IDEA XML File -- Filing Summary XML 143K
86: EXCEL IDEA Workbook of Financial Reports XLSX 93K
8: EX-101.INS XBRL Instance -- heb-20171231 XML 2.08M
10: EX-101.CAL XBRL Calculations -- heb-20171231_cal XML 163K
11: EX-101.DEF XBRL Definitions -- heb-20171231_def XML 729K
12: EX-101.LAB XBRL Labels -- heb-20171231_lab XML 1.20M
13: EX-101.PRE XBRL Presentations -- heb-20171231_pre XML 910K
9: EX-101.SCH XBRL Schema -- heb-20171231 XSD 209K
88: ZIP XBRL Zipped Folder -- 0001493152-18-004291-xbrl Zip 162K
AMENDMENT NO. 1 TO
EARLY ACCESS AGREEMENT
This First Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of December 13, 2106 (the “Amendment No. 1 Effective Date”).
RECITALS
WHEREAS, HEMISPHERX and IMPATIENTS are Parties to and Early Access Agreement for HEMISPHERX’S Product, Ampligen (rintatolimod);
WHEREAS, the Parties wish to amend the Agreement as set forth below;
NOW, THEREFORE, the Parties hereby agree as follows:
Definitions and References. Except as set forth herein, capitalized terms not otherwise defined or amended in the Amendment shall have the meaning ascribed to them in the Agreement. References to Articles or Sections are the same with all of their subparts as they appear in the Agreement.
| 1. | Amendment to the Agreement: Effective as of the Amendment No. 1 Effective Date, the Agreement shall be amended as follows: |
In Clause 1.10 the text “and/or treatment of pancreatic cancer” shall be added to the definition of Field, such that Clause 1.10 reads
“Field” means treatment of chronic fatigue syndrome and/or the treatment of pancreatic cancer.
In Exhibit 9 the text “for patients with Chronic Fatigue Syndrome” shall be added in the second line such that the first paragraph reads:
To the extent permitted by Applicable Law, IMPATIENTS shall use its reasonable commercial efforts to collect the following data in relation to the EAP for patients with Chronic Fatigue Syndrome;
| 2. | Effect of the Amendment. From and after the Amendment No. 1 Effective Date, all references to the Agreement shall mean the Agreement as amended by this Agreement. Except as expressly amended by the Amendment, all of the provisions of the original Early Access Program shall remain in full force and effect. |
C:
| C: 1 |
IN WITNESS WHEREOF, the respective Parties hereto have duly executed this Amendment as of the Amendment No. 1 Effective Date above. The persons executing this Amendment represent and warrant that they have the full power and authority to enter into this Amendment on behalf of the persons or entities for whom they are signing.
| HEMISPHERX BIOPHARMA, INC. | ||
| a Delaware corporation | ||
| By: | /s/ Ronald Brus, MD | |
| Title: | CEO | |
| IMPATIENTS N.V. | ||
| a Dutch limited liability company | ||
| By: | /s/ Thomas K. Equals | |
| Title: | Chairman and CEO | |
C:
| 2 |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA 5/13/22 AIM ImmunoTech Inc. 10-Q 3/31/22 68:5.6M M2 Compliance LLC/FA 3/31/22 AIM ImmunoTech Inc. 10-K 12/31/21 90:9.3M M2 Compliance LLC/FA 3/31/21 AIM ImmunoTech Inc. 10-K 12/31/20 94:7.6M M2 Compliance LLC/FA |